September 30, 2016 3:51 PM ET


Company Overview of HemoShear Therapeutics, LLC

Company Overview

HemoShear Therapeutics, LLC discovers novel biological targets and drugs to treat a range of metabolic disorders that have significant unmet patient need. It develops and validates REVEAL-Tx, a transformational and proprietary drug discovery platform that provides unprecedented insights into human disease biology by replicating human disease. The company focuses on the family of inherited disorders called Organic Acidemias with known mutations and strong clinical hypotheses for drug targets; and on drug discovery in Nonalcoholic Steatohepatitis, a serious, chronic, and progressive liver disease. HemoShear Therapeutics, LLC was formerly known as HemoShear, LLC and changed its name to HemoShea...

501 Locust Avenue

Suite 301

Charlottesville, VA 22902

United States

Founded in 2008





Key Executives for HemoShear Therapeutics, LLC

Chairman and Chief Executive Officer
Age: 64
Co-Founder and Chief Scientific Officer
Co-Founder, Vice President of Research & Development and Director
Vice President of Operations
General Counsel and Director
Age: 56
Compensation as of Fiscal Year 2016.

HemoShear Therapeutics, LLC Key Developments

HemoShear Therapeutics Appoints H. Thomas Watkins to its Board of Directors

HemoShear Therapeutics reported the appointment of H. Thomas Watkins to its Board of Directors. Watkins is the former president and chief executive officer of Human Genome Sciences and also served as the chairman of the Biotechnology Industry Organization.

HemoShear Names Vincent E. Aurentz as President

HemoShear announced that Vincent E. Aurentz, Chief Business Officer, has been named President of HemoShear. Mr. Aurentz will be responsible for leading HemoShear's scientific and business development strategies, as well as public relations and marketing, in addition to his existing business development responsibilities. He will continue to report directly to CEO and Chairman Jim Powers, and will also join HemoShear's Board of Managers. Mr. Aurentz's appointment will utilize his more than 25 years of experience in the pharmaceutical and biotech industry as an entrepreneur and pharmaceutical R&D executive. He spent almost nine years with Merck KGaA and Merck Serono where he was Executive Vice President, Portfolio Development and member of the Executive Management Board as well as Head of Global Business Development. He was also recently Executive Vice President at Quintiles.

HemoShear Completes First Phase of Development of Novel Cancer Drug Discovery Platform

HemoShear announced that it has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations. Funded by a contract with the NCI, HemoShear is developing a series of tumor models that recreate a wide variety of cancers for discovery of new drugs. Using their new platform, HemoShear was able to successfully replicate human therapeutic response to Cisplatin, a drug approved to treat non-small cell lung carcinomoa, at a therapeutically-relevant concentration. Similarly, HemoShear evaluated two other drugs currently in clinical studies and confirmed a therapeutic response. When evaluated in traditional cell culture systems and mouse studies, the same dose of Cisplatin does not show a response. HemoShear's findings reinforce the need to test cancer drug candidates under more human-relevant tumor conditions. HemoShear's translational tissue systems apply physiological blood flow characteristics to human tissue to restore its in vivo biology, using material from HemoShear's biorepository and interpreting data with cutting edge computational analytics. In phase I of the NCI-funded program, HemoShear demonstrated that NSCLC tumor structure, biology, and molecular signaling pathways are restored in the HemoShear platform.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Private Placement
February 3, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact HemoShear Therapeutics, LLC, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at